Cargando…
JP‐1366: A novel and potent potassium‐competitive acid blocker that is effective in the treatment of acid‐related diseases
The global prevalence of GERD is substantially increasing each year, and GERD is a chronic disease that reduces the quality of life of patients. The efficacy of conventional drugs is diverse, and most require long‐term or lifetime administration; thus, the development of more effective therapeutic a...
Autores principales: | Ku, Jin Mo, Cho, Jin Hee, Kim, Kangjeon, Kim, Ji Yoon, Kim, Jong Yup, Kim, John, Cha, Hyunju, Cheon, Banyoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163344/ https://www.ncbi.nlm.nih.gov/pubmed/37147903 http://dx.doi.org/10.1002/prp2.1090 |
Ejemplares similares
-
Protonated Form: The Potent Form of Potassium-Competitive Acid Blockers
por: Luo, Hua-Jun, et al.
Publicado: (2014) -
Pathophysiology of Potassium-competitive Acid Blocker–refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test
por: Masaoka, Tatsuhiro, et al.
Publicado: (2018) -
Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases
por: Oshima, Tadayuki, et al.
Publicado: (2018) -
Role of potassium-competitive acid blockers in eradication of Helicobacter pylori infection
por: Kim, Tae Ho
Publicado: (2023) -
Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
por: Son, Mijeong, et al.
Publicado: (2022)